Editorial
321 Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?
F A Haas Roux, A Dora

Clinical and epidemiological research
323 Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D A Henberg, A Peri, K Kalunian, Y Tanaka, M B Urowitz, R W Hoffman, M Morgan-Cox, N Domen, N Sjolund, H Kottstein, D Wallace

322 Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

341 Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration

348 Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

356 Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
J Karlsson, J F Petersen, S Steventon, L Klareskog, R V van Vollenhoven, K Lundberg

362 Suitability Of Nitinoin In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

368 The offspring of people with a total knee replacement have a higher risk of worsening knee pain over 8 years
F Fan, C Ding, T Winzenberg, H Khan, J Karlset-Pelletier, J-P Pelletier, F Cicuttini, G Jones

374 Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis
D P Tasker, E V Vollmann, C-H Tseng, H J Kim, J Coldin, P Clements, D Furo, D Khaama, E Kleeberg, M D Rob, R Elshoff

382 Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

390 Synovitis in knee osteoarthritis: a precursor of disease?
A Anagnostou, G K Korob, A Guermazzz, J L Roumer, R M Boudreau, J M Hannon, D J Hunter

396 Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

402 Global ultrasound assessment of structural lesions in osteoarthritis: a reliability study by the OMERACT ultrasound group on scoring cartilage and osteophytes in finger joints
H B Hammer, A Lagouge, A Mathiesen, E Filipuccia, F Gandjbakhch, A M Kritikos, G M Helen, G Kar, B J Welkerfelt, P Aegerter, M A D Agostino

408 Long-term effects of securikumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study

Discipline: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence provided by the World Association of Medical Editors and the code on good publication practice offered by Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions or the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd, Tavistock Square, London WC1H 9UX, UK. (ISSN: 0003-4967 (print); e-ISSN: 1468-2069 (online).) Impact Factor: 10.377

Disclaimer: ARD is published by BMJ Publishing Group Ltd on behalf of the British Medical Association and the European League Against Rheumatism. The owners prohibit the use of this for other than personal or non-commercial purposes and are not responsible therefor. Statements in this publication are the responsibility of the authors or advertisers and not the authors’ institutions or the BMJ unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of this journal or any information therein whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

This article has been made freely available online under the BMJ Journals Open Access scheme. See http://ard.bmj.com/site/about/guidelines.xhtml#openaccess
Basic and translational research

**413** Rsk2 controls synovial fibroblast hyperplasia and the course of arthritis
A Derer, C Bohm, B Greitsch, J R Caun, A Groitzschau, M Stock, S Bohm, B Schuhert, U Gaipl, G Schett, J H Hueber, J-P David

**422** The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts

**430** Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDACS expression

**439** Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation
C C Thornton, C C Retornaz, D Calay, C M Birdsey, A Bauer, H Mylroie, J J Boyle, J C Mason

**449** Oxidative changes and signalling pathways are pivotal in initiating age-related changes in articular cartilage
W Hui, D A Young, A D Rowan, X Xu, T E Cawston, C J Proctor

**459** A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment
R Spreafico, M Rossetti, J van Loosdregt, C A Wallace, M Massa, S Magni-Manzoni, M Cattorno, A Martini, D J Lovell, S Albani

**466** IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis
A E Anderson, A G Pratt, M A K Sedhom, J P Doran, C Roulledge, B Hargreaves, P M Brown, K A Le Cao, J D Isaac, K Thomas

**474** Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice
M Manetti, J Rosa, M Fazi, S Ciuducci, P Carmeliet, I. Ibar-Manneschi, M Matteucci-Cerin

Correction

**473** Correction

Electronic pages

**Correspondence**

**e10** From BLISS to ILLUMINATE studies: “Blys repetita placenta”?
I Chiche, N Jourde-Chiche, F Retornaz, D Cornec

**e11** Further thoughts about the ILLUMINATE studies of tabalumab in SLE
D Isenberg

Thank you to our reviewers

**e12** Thank you to our reviewers 2015